Cystic hygroma: OK-432 is superior to surgery

Abstract The outcome of treatment with picibanil (OK-432) for lymphatic malformation is analysed retrospectively. The solution was instilled in the cysts upon aspiration of lymph fluid under ultrasound-scan guidance. In 13 patients, a follow-up time longer than 3 months was present. No permanent side effects were noted. A favourable or very favourable result was noted in cases with macrocystic lesions, while microcystic manifestations were generally unaffected by the treatment. OK-432 should be considered for the initial treatment of lymphangioma/lymphatic malformation.